ACT Approved for Increasing Dosage in Macular Degeneration Clinical Trials

ACT (Advanced Cell Technology Inc) is a biotechnology company that specializes in the development of cellular therapies for the treatment of diseases and conditions. Advanced Cell is developing a treatment for Dry Macular Degeneration from human embryonic stem cells.

An independent board has authorized Advanced Cell Technology Inc. to treat more patients with its experimental treatment for macular degeneration, and to increase dosage.

For more info:

http://www.telegram.com/article/20120709/NEWS/120709574/1002/business

http://www.advancedcell.com/

http://www.advancedcell.com/news-and-media/press-releases/act-secures-approval-to-proceed-with-increased-rpe-dosage-for-patients-in-clinical-trial-for-dry-amd/in

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: